본문

서브메뉴

Computational Metabolomics for Bioactivity-Driven Classification in Natural Products Drug Discovery and Opioid Detection
Computational Metabolomics for Bioactivity-Driven Classification in Natural Products Drug ...
Computational Metabolomics for Bioactivity-Driven Classification in Natural Products Drug Discovery and Opioid Detection

Detailed Information

자료유형  
 학위논문 서양
최종처리일시  
20260202103613
ISBN  
9798315733874
DDC  
615
저자명  
Brittin, Nathaniel Jacob.
서명/저자  
Computational Metabolomics for Bioactivity-Driven Classification in Natural Products Drug Discovery and Opioid Detection
발행사항  
[Sl] : The University of Wisconsin - Madison, 2025
발행사항  
Ann Arbor : ProQuest Dissertations & Theses, 2025
형태사항  
175 p
주기사항  
Source: Dissertations Abstracts International, Volume: 86-11, Section: B.
주기사항  
Advisor: Bugni, Tim S.
학위논문주기  
Thesis (Ph.D.)--The University of Wisconsin - Madison, 2025.
초록/해제  
요약The rise of multidrug-resistant (MDR) pathogens and the proliferation of synthetic opioids pose urgent threats to global health, demanding innovative approaches in both drug discovery and forensic analysis. This dissertation presents a multidisciplinary framework that leverages high-resolution mass spectrometry, yeast chemical genomics (YCG), and machine learning (ML) to address these dual challenges across two different but connected domains: natural product discovery and clinical toxicology (Chapter 1).To accelerate the identification of structurally novel and mechanistically distinct antifungal agents, we developed a high-throughput screening pipeline that integrates LC-MS/MS-based metabolomics with YCG profiling (Chapter 2). Nearly 40,000 bacterial extract fractions from diverse microbiomes were screened for antifungal activity, with hits prioritized based on both chemical-genetic interaction signatures and computational metabolomics identifications. This dual-platform approach enabled functional dereplication by linking mass spectral features to both known drug classes and unexplored bioactive compounds, streamlining the prioritization of lead scaffolds for further development.To further enhance the dereplication and prioritization of small molecules, we trained ML classifiers on in-silico MS/MS fingerprints to assign natural products to 21 pharmacophore-defined drug classes (Chapter 3). These classifiers achieved 93% accuracy in multiclass tasks and consistently outperformed state-of-the-art tools (e.g., CANOPUS) across in-silico, GNPS, and experimental datasets. When applied to microbial extracts, the models enabled rapid classification of bioactivity, even in the absence of direct structural matches, expanding the accessible chemical and functional space for antimicrobial discovery.The second major focus of this dissertation is the development of ML-based models for opioid detection from clinical LC-MS/MS data (Chapter 4). Classifiers for morphinan, fentanyl, and nitazene opioids were trained on simulated molecular fingerprints and validated using GNPS spectra, CDC FAS Kit reference materials, and anonymized clinical blood and urine samples. Morphinan and fentanyl models demonstrated exceptional performance, increasing compound detection and sample coverage by 90-600% and 33-400%, respectively, compared to traditional spectral library searches. Although the nitazene classifier performed well in controlled settings, clinical application highlighted the need for improved coverage and training data.Collectively, these studies illustrate how integrating high-resolution metabolomics with machine learning and functional genomics can transform both small molecule discovery and public health surveillance, enabling scalable, structure-informed detection of bioactive natural products and emerging synthetic opioids.
일반주제명  
Pharmaceutical sciences
일반주제명  
Chemistry
일반주제명  
Computational chemistry
일반주제명  
Bioinformatics
일반주제명  
Analytical chemistry
키워드  
Chemical genomics
키워드  
Drug discovery
키워드  
Machine learning
키워드  
Mass spectrometry
키워드  
Metabolomics
키워드  
Natural products
기타저자  
The University of Wisconsin - Madison Pharmaceutical Sciences
기본자료저록  
Dissertations Abstracts International. 86-11B.
전자적 위치 및 접속  
로그인 후 원문을 볼 수 있습니다.

MARC

 008260126s2025        us                              c    eng  d
■001000017357886
■00520260202103613
■006m          o    d                
■007cr#unu||||||||
■020    ▼a9798315733874
■035    ▼a(MiAaPQ)AAI32043908
■040    ▼aMiAaPQ▼cMiAaPQ
■0820  ▼a615
■1001  ▼aBrittin,  Nathaniel  Jacob.
■24510▼aComputational  Metabolomics  for  Bioactivity-Driven  Classification  in  Natural  Products  Drug  Discovery  and  Opioid  Detection
■260    ▼a[Sl]▼bThe  University  of  Wisconsin  -  Madison▼c2025
■260  1▼aAnn  Arbor▼bProQuest  Dissertations  &  Theses▼c2025
■300    ▼a175  p
■500    ▼aSource:  Dissertations  Abstracts  International,  Volume:  86-11,  Section:  B.
■500    ▼aAdvisor:  Bugni,  Tim  S.
■5021  ▼aThesis  (Ph.D.)--The  University  of  Wisconsin  -  Madison,  2025.
■520    ▼aThe  rise  of  multidrug-resistant  (MDR)  pathogens  and  the  proliferation  of  synthetic  opioids  pose  urgent  threats  to  global  health,  demanding  innovative  approaches  in  both  drug  discovery  and  forensic  analysis.  This  dissertation  presents  a  multidisciplinary  framework  that  leverages  high-resolution  mass  spectrometry,  yeast  chemical  genomics  (YCG),  and  machine  learning  (ML)  to  address  these  dual  challenges  across  two  different  but  connected  domains:  natural  product  discovery  and  clinical  toxicology  (Chapter  1).To  accelerate  the  identification  of  structurally  novel  and  mechanistically  distinct  antifungal  agents,  we  developed  a  high-throughput  screening  pipeline  that  integrates  LC-MS/MS-based  metabolomics  with  YCG  profiling  (Chapter  2).  Nearly  40,000  bacterial  extract  fractions  from  diverse  microbiomes  were  screened  for  antifungal  activity,  with  hits  prioritized  based  on  both  chemical-genetic  interaction  signatures  and  computational  metabolomics  identifications.  This  dual-platform  approach  enabled  functional  dereplication  by  linking  mass  spectral  features  to  both  known  drug  classes  and  unexplored  bioactive  compounds,  streamlining  the  prioritization  of  lead  scaffolds  for  further  development.To  further  enhance  the  dereplication  and  prioritization  of  small  molecules,  we  trained  ML  classifiers  on  in-silico  MS/MS  fingerprints  to  assign  natural  products  to  21  pharmacophore-defined  drug  classes  (Chapter  3).  These  classifiers  achieved  93%  accuracy  in  multiclass  tasks  and  consistently  outperformed  state-of-the-art  tools  (e.g.,  CANOPUS)  across  in-silico,  GNPS,  and  experimental  datasets.  When  applied  to  microbial  extracts,  the  models  enabled  rapid  classification  of  bioactivity,  even  in  the  absence  of  direct  structural  matches,  expanding  the  accessible  chemical  and  functional  space  for  antimicrobial  discovery.The  second  major  focus  of  this  dissertation  is  the  development  of  ML-based  models  for  opioid  detection  from  clinical  LC-MS/MS  data  (Chapter  4).  Classifiers  for  morphinan,  fentanyl,  and  nitazene  opioids  were  trained  on  simulated  molecular  fingerprints  and  validated  using  GNPS  spectra,  CDC  FAS  Kit  reference  materials,  and  anonymized  clinical  blood  and  urine  samples.  Morphinan  and  fentanyl  models  demonstrated  exceptional  performance,  increasing  compound  detection  and  sample  coverage  by  90-600%  and  33-400%,  respectively,  compared  to  traditional  spectral  library  searches.  Although  the  nitazene  classifier  performed  well  in  controlled  settings,  clinical  application  highlighted  the  need  for  improved  coverage  and  training  data.Collectively,  these  studies  illustrate  how  integrating  high-resolution  metabolomics  with  machine  learning  and  functional  genomics  can  transform  both  small  molecule  discovery  and  public  health  surveillance,  enabling  scalable,  structure-informed  detection  of  bioactive  natural  products  and  emerging  synthetic  opioids.
■590    ▼aSchool  code:  0262.
■650  4▼aPharmaceutical  sciences
■650  4▼aChemistry
■650  4▼aComputational  chemistry
■650  4▼aBioinformatics
■650  4▼aAnalytical  chemistry
■653    ▼aChemical  genomics
■653    ▼aDrug  discovery
■653    ▼aMachine  learning
■653    ▼aMass  spectrometry
■653    ▼aMetabolomics
■653    ▼aNatural  products
■690    ▼a0572
■690    ▼a0485
■690    ▼a0219
■690    ▼a0486
■690    ▼a0715
■71020▼aThe  University  of  Wisconsin  -  Madison▼bPharmaceutical  Sciences.
■7730  ▼tDissertations  Abstracts  International▼g86-11B.
■790    ▼a0262
■791    ▼aPh.D.
■792    ▼a2025
■793    ▼aEnglish
■85640▼uhttp://www.riss.kr/pdu/ddodLink.do?id=T17357886▼nKERIS▼z이  자료의  원문은  한국교육학술정보원에서  제공합니다.

Preview

Export

ChatGPT Discussion

AI Recommended Related Books


    New Books MORE
    Statistics for the past 3 years. Go to brief

    Подробнее информация.

    • Бронирование
    • не существует
    • моя папка
    • Первый запрос зрения
    • Non-Book Loan Application
    • Nighttime Book Loan Application
    материал
    Reg No. Количество платежных Местоположение статус Ленд информации
    TF15050 전자도서 대출가능 My Folder 부재도서신고 비도서대출신청 야간 도서대출신청

    * Бронирование доступны в заимствований книги. Чтобы сделать предварительный заказ, пожалуйста, нажмите кнопку бронирование

    Books borrowed together with this book

    Related Popular Books

    Available after logging in.